IP Library Granted Patent US 8,067,450
Granted Patent B2
US 8,067,450 · App. 12/677,541 · Granted Nov 29, 2011

Thiazolidinedione analogues for the treatment of metabolic diseases

Assignee: Metabolic Solutions Development Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,450
App. No.
12/677,541
Granted
Nov 29, 2011
Kind
B2
Abstract

The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R 1 and R 4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R 2 is halo, hydroxy, or optionally substituted aliphatic, and R′ 2 is H, or R 2 and R′ 2 together form oxo; R 3 is H; and Ring A is a phenyl.

Claims (6)

1. A pharmaceutical composition comprising the compound

and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , further comprising a diuretic selected from hydrochlorothiazide, chlorothaladone, chlorothiazide, or any combination thereof; a statin selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, simvastatin, rosuvastatin, pravastatin, or any combination thereof; an angiotension II receptor blocker selected from losartan, olmesartan, telmisartan, or any combination thereof; an ACE inhibitor selected from ramipril, captopril, enalapril, or any combination thereof; calcium channel blocker selected from amlodipine; or combination thereof.

3. The pharmaceutical composition of claim 1 , further comprising a glucocorticoid agonist selected from cortisone, hydrocortisone, predisone, prednisolone, methylprednisolone, betamethasone, triamcinolone, or any combination thereof.

4. A compound selected from:

5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione.

Assignments (6)
CHANGE OF NAME Recorded May 12, 2017
From: OCTETA THERAPEUTICS, LLC
To: CIRIUS THERAPEUTICS, INC.
Reel/Frame 042457/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC
To: OCTETA THERAPEUTICS, LLC
Reel/Frame 038996/0394 →
RELEASE OF SECURITY INTEREST Recorded May 19, 2016
From: PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK)
To: METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC
Reel/Frame 038652/0097 →
SECURITY AGREEMENT Recorded Feb 5, 2014
From: METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC
To: SQUARE 1 BANK
Reel/Frame 032162/0330 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 024407 FRAME 0158. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 24, 2010
From: COLCA, GERARD R.; GADWOOD, ROBERT C.; PARKER, TIM
To: METABOLIC SOLUTIONS DEVELOPMENT COMPANY
Reel/Frame 024430/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2010
From: COLCA, GERARD R.; GADWOOD, ROBERT C.; PARKER, TIM
To: METABOLIC SOULTIONS DEVELOPMENT COMPANY
Reel/Frame 024407/0158 →
Continuity (2)
Provisional Application 60972639 · Sep 14, 2007
Related Publication 20100222399A1 · Sep 2, 2010